Adverse Events The overall safety evaluation of NEXAVAR is based on 1286 cancer patients who received NEXAVAR as monotherapy and 165 patients who received NEXAVAR concurrently with chemotherapy. A total of 346 patients were exposed to NEXAVAR monotherapy for greater than 6 months . A total of 664 RCC patients received NEXAVAR monotherapy, of whom 215 were treated for at least 6 months. A full presentation of safety information is provided in the Product Monograph. Clinically significant adverse events included hypertension (17% for sorafenib vs 2% for placebo), hemorrhage (15% sorafenib vs 8% for placebo), and cardiac ischemia / infarction (2.9% for sorafenib vs 0.4% for placebo). In a randomized, placebo-controlled study in locally advanced / metastatic RCC, the most common treatment-emergent adverse events reported with sorafenib vs placebo were rash (40% vs 16%), diarrhea (43% vs 13%), hand-foot skin reaction (30% vs 7%), fatigue (37% vs 28%), and hypertension (17% vs 2%). Most adverse events observed with NEXAVAR were CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) Grade 1 and 2. CTCAE Grade 4 drug-related adverse events were rare, reported in 7% of patients receiving NEXAVAR compared to 6% of patients receiving placebo.
PGL Price at posting:
0.0¢ Sentiment: Buy Disclosure: Not Held
